References
- Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics. 2008;5:548–57.
- Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009;80:1060–8.
- Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommen-dations. Expert Opin Pharmacother. 2009;10:1183–90.
- Dalakas MC. Intravenous immunoglobulin in autoimmune neuro-muscular diseases. JAMA. 2004;291:2367–75.
- Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
- Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermat-omyositis. Mod Rheumatol. 2008;18:34–44.
- Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immuno-globulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.
- Genevay S, Saudan-Kister A, Guerne PA. Intravenous gamma-globulins in refractory polymyositis: lower dose for maintenance treatment is effective. Ann Rheum Dis. 2001;60:635–6.